Agents, methods and uses thereof

WO2026038050A3PCT designated stage Publication Date: 2026-03-26CREASALLIS LTD
View PDF 6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-08-14
Publication Date
2026-03-26

AI Technical Summary

Technical Problem

Antibody-based therapies face poor penetration into the tumour microenvironment (TME) due to their large size, leading to sub-optimal efficacy and the need for higher doses, which can be toxic, and smaller fragments lack an Fc region, reducing half-life and efficacy.

Method used

Incorporating a cleavable domain between a therapeutic domain and a stabilisation domain, allowing selective cleavage by tumour-specific proteases to release the therapeutic domain for enhanced penetration and binding to antigens within the TME.

Benefits of technology

Improves the penetrability and specificity of therapeutic agents into tumours, enhancing their efficacy by allowing deeper penetration into hypoxic regions and maintaining therapeutic function post-cleavage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GB2025051809_26032026_PF_FP_ABST
    Figure GB2025051809_26032026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to methods and conjugates to improve the penetrability of biological substances into the tumour microenvironment (TME) for therapeutic purposes and / or to improve the treatment efficacy, suitably the agent comprises at least: i a therapeutic domain; ii. a cleavable domain; iii. a stabilisation domain; and iv. a fusion domain. The invention also relates to Fc-fusion molecules comprising an Fc region and a fusion domain, and their therapeutic uses.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Bispecific her2 antibodies and methods of use

    WO2015091738A1

  • Tumor targeting conjugates and methods of use thereof

    WO2018140831A2

  • Multispecific binding proteins

    WO2020160189A1

  • Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens

    WO2020181145A1

  • Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof

    WO2020229553A1